| Advanced Breast Cancer Therapies | Lifetime | 2 | FR 1 | 99.94 |
| Cancer Genomics and Diagnostics | Lifetime | 19 | FR 1 | 99.92 |
| HER2/EGFR in Cancer Research | Lifetime | 12 | FR 1 | 99.92 |
| Cancer Treatment and Pharmacology | Lifetime | 29 | FR 2 | 99.87 |
| Breast Cancer Treatment Studies | Lifetime | 31 | FR 1 | 99.86 |
| Lung Cancer Treatments and Mutations | Lifetime | 90 | FR 6 | 99.73 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 31 | FR 1 | 99.64 |
| Cancer Diagnosis and Treatment | Lifetime | 104 | FR 3 | 99.17 |
| Extracellular vesicles in disease | Lifetime | 76 | FR 8 | 98.97 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 199 | FR 19 | 99.50 |
| Fibroblast Growth Factor Research | Lifetime | 41 | FR 3 | 98.92 |
| Cancer-related Molecular Pathways | Lifetime | 171 | FR 5 | 99.26 |
| Immunotherapy and Immune Responses | Lifetime | 664 | FR 25 | 98.95 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 500 | FR 39 | 98.66 |
| Kruppel-like factors research | Lifetime | 108 | FR 3 | 97.53 |
| Gene expression and cancer classification | Lifetime | 268 | FR 4 | 97.40 |
| Lung Cancer Research Studies | Lifetime | 543 | FR 28 | 98.07 |
| Genetic factors in colorectal cancer | Lifetime | 747 | FR 25 | 97.55 |
| Cancer Cells and Metastasis | Lifetime | 887 | FR 29 | 96.67 |
| Breast Lesions and Carcinomas | Lifetime | 536 | FR 21 | 96.53 |
| PARP inhibition in cancer therapy | Lifetime | 425 | FR 22 | 95.23 |
| BRCA gene mutations in cancer | Lifetime | 777 | FR 20 | 95.48 |
| Brain Metastases and Treatment | Lifetime | 918 | FR 47 | 94.74 |
| Cancer Genomics and Diagnostics | 2021-2025 | 6 | FR 1 | 99.92 |
| Cancer Diagnosis and Treatment | 2021-2025 | 2 | FR 1 | 99.18 |
| Advanced Breast Cancer Therapies | 2021-2025 | 9 | FR 1 | 99.87 |
| Breast Cancer Treatment Studies | 2021-2025 | 15 | FR 1 | 99.81 |
| Cancer Treatment and Pharmacology | 2021-2025 | 10 | FR 1 | 99.79 |
| HER2/EGFR in Cancer Research | 2021-2025 | 10 | FR 1 | 99.85 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 8 | FR 1 | 98.26 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 105 | FR 7 | 99.32 |
| Cancer-related Molecular Pathways | 2021-2025 | 21 | FR 1 | 98.38 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 291 | FR 19 | 98.88 |
| Genetic factors in colorectal cancer | 2021-2025 | 320 | FR 14 | 93.81 |
| Lung Cancer Research Studies | 2021-2025 | 426 | FR 21 | 94.93 |
| Brain Metastases and Treatment | 2021-2025 | 254 | FR 9 | 93.01 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 613 | FR 35 | 94.04 |
| PARP inhibition in cancer therapy | 2021-2025 | 399 | FR 26 | 88.77 |
| BRCA gene mutations in cancer | 2021-2025 | 985 | FR 23 | 80.53 |
| Cancer-related cognitive impairment studies | 2021-2025 | 523 | FR 11 | 75.13 |
| Chemotherapy-related skin toxicity | 2021-2025 | 588 | FR 18 | 46.00 |
